Welcome to Skilled in the Art. I'm Law.com IP reporter Scott Graham. Here's what's crossing my desk this week:

|
  • It's the Battle of Big Pharma as Amgen, Sanofi and Regeneron return to the Federal Circuit to fight over ground rules for antibody patents, with Bristol-Myers Squibb, Merck, Eli Lilly and Pfizer along as amici.
|
  • BlackBerry faces the first of two big hurdles to revive its messaging patent suit against Facebook and Snap.
|
  • Vizzi overcomes Brizzi in the early round of a trademark dispute over hard seltzer drinks.
|
  • CareDx organ transplant patents still eligible following extra judicial scrutiny.

As always you can email me your feedback and follow me on Twitter.

Arnold & Porter's Matt Wolf, left, and MoloLamken's Jeff Lamken
 

|

Who's Arguing—Back to the Biotech Future

I will never forget the first Federal Circuit argument over Amgen's Repatha cholesterol drug patents. Three years ago, Paul Clement and Daryl Joseffer squared off in a courtroom packed so tight with bio-pharma industry lawyers that people took seats on the stairs.